Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse

Yang Pu, Meng Xu, Yong Liang, Kaiting Yang, Yajun Guo, Xuanming Yang, Yang Xin Fu

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Surgical and medical androgen deprivation therapy (ADT) is a cornerstone for prostate cancer treatment, but relapse usually occurs. We herein show that orchiectomy synergizes with immunotherapy, whereas the more widely used treatment of medical ADT involving androgen receptor (AR) antagonists suppresses immunotherapy. Furthermore, we observed that the use of medical ADT could unexpectedly impair the adaptive immune responses through interference with initial T cell priming rather than in the reactivation or expansion phases. Mechanistically, we have revealed that inadvertent immunosuppression might be potentially mediated by a receptor shared with g-aminobutyric acid. Our data demonstrate that the timing and dosing of antiandrogens are critical to maximizing the antitumor effects of combination therapy. This study highlights an underappreciated mechanism of AR antagonist-mediated immunosuppression and provides a new strategy to enhance immune response and prevent the relapse of advanced prostate cancer.

Original languageEnglish (US)
Article numberra47
JournalScience Translational Medicine
Volume8
Issue number333
DOIs
StatePublished - Apr 6 2016

Fingerprint

Androgen Receptor Antagonists
Prostatic Neoplasms
T-Lymphocytes
Recurrence
Androgens
Neoplasms
Immunotherapy
Immunosuppression
Therapeutics
Aminobutyrates
Androgen Antagonists
Orchiectomy
Adaptive Immunity

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse. / Pu, Yang; Xu, Meng; Liang, Yong; Yang, Kaiting; Guo, Yajun; Yang, Xuanming; Fu, Yang Xin.

In: Science Translational Medicine, Vol. 8, No. 333, ra47, 06.04.2016.

Research output: Contribution to journalArticle

Pu, Yang ; Xu, Meng ; Liang, Yong ; Yang, Kaiting ; Guo, Yajun ; Yang, Xuanming ; Fu, Yang Xin. / Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse. In: Science Translational Medicine. 2016 ; Vol. 8, No. 333.
@article{26653f134afb429ba4139557cca4a8ed,
title = "Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse",
abstract = "Surgical and medical androgen deprivation therapy (ADT) is a cornerstone for prostate cancer treatment, but relapse usually occurs. We herein show that orchiectomy synergizes with immunotherapy, whereas the more widely used treatment of medical ADT involving androgen receptor (AR) antagonists suppresses immunotherapy. Furthermore, we observed that the use of medical ADT could unexpectedly impair the adaptive immune responses through interference with initial T cell priming rather than in the reactivation or expansion phases. Mechanistically, we have revealed that inadvertent immunosuppression might be potentially mediated by a receptor shared with g-aminobutyric acid. Our data demonstrate that the timing and dosing of antiandrogens are critical to maximizing the antitumor effects of combination therapy. This study highlights an underappreciated mechanism of AR antagonist-mediated immunosuppression and provides a new strategy to enhance immune response and prevent the relapse of advanced prostate cancer.",
author = "Yang Pu and Meng Xu and Yong Liang and Kaiting Yang and Yajun Guo and Xuanming Yang and Fu, {Yang Xin}",
year = "2016",
month = "4",
day = "6",
doi = "10.1126/scitranslmed.aad5659",
language = "English (US)",
volume = "8",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "333",

}

TY - JOUR

T1 - Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse

AU - Pu, Yang

AU - Xu, Meng

AU - Liang, Yong

AU - Yang, Kaiting

AU - Guo, Yajun

AU - Yang, Xuanming

AU - Fu, Yang Xin

PY - 2016/4/6

Y1 - 2016/4/6

N2 - Surgical and medical androgen deprivation therapy (ADT) is a cornerstone for prostate cancer treatment, but relapse usually occurs. We herein show that orchiectomy synergizes with immunotherapy, whereas the more widely used treatment of medical ADT involving androgen receptor (AR) antagonists suppresses immunotherapy. Furthermore, we observed that the use of medical ADT could unexpectedly impair the adaptive immune responses through interference with initial T cell priming rather than in the reactivation or expansion phases. Mechanistically, we have revealed that inadvertent immunosuppression might be potentially mediated by a receptor shared with g-aminobutyric acid. Our data demonstrate that the timing and dosing of antiandrogens are critical to maximizing the antitumor effects of combination therapy. This study highlights an underappreciated mechanism of AR antagonist-mediated immunosuppression and provides a new strategy to enhance immune response and prevent the relapse of advanced prostate cancer.

AB - Surgical and medical androgen deprivation therapy (ADT) is a cornerstone for prostate cancer treatment, but relapse usually occurs. We herein show that orchiectomy synergizes with immunotherapy, whereas the more widely used treatment of medical ADT involving androgen receptor (AR) antagonists suppresses immunotherapy. Furthermore, we observed that the use of medical ADT could unexpectedly impair the adaptive immune responses through interference with initial T cell priming rather than in the reactivation or expansion phases. Mechanistically, we have revealed that inadvertent immunosuppression might be potentially mediated by a receptor shared with g-aminobutyric acid. Our data demonstrate that the timing and dosing of antiandrogens are critical to maximizing the antitumor effects of combination therapy. This study highlights an underappreciated mechanism of AR antagonist-mediated immunosuppression and provides a new strategy to enhance immune response and prevent the relapse of advanced prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=84963589359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963589359&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.aad5659

DO - 10.1126/scitranslmed.aad5659

M3 - Article

C2 - 27053771

AN - SCOPUS:84963589359

VL - 8

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 333

M1 - ra47

ER -